RT Journal Article
T1 Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.
A1 Kalincik, Tomas
A1 Spelman, Timothy
A1 Trojano, Maria
A1 Duquette, Pierre
A1 Izquierdo, Guillermo
A1 Grammond, Pierre
A1 Lugaresi, Alessandra
A1 Hupperts, Raymond
A1 Cristiano, Edgardo
A1 Van Pesch, Vincent
A1 Grand'Maison, Francois
A1 La Spitaleri, Daniele
A1 Rio, Maria Edite
A1 Flechter, Sholmo
A1 Oreja-Guevara, Celia
A1 Giuliani, Giorgio
A1 Savino, Aldo
A1 Amato, Maria Pia
A1 Petersen, Thor
A1 Fernandez-Bolanos, Ricardo
A1 Bergamaschi, Roberto
A1 Iuliano, Gerardo
A1 Boz, Cavit
A1 Lechner-Scott, Jeannette
A1 Deri, Norma
A1 Gray, Orla
A1 Verheul, Freek
A1 Fiol, Marcela
A1 Barnett, Michael
A1 van Munster, Erik
A1 Santiago, Vetere
A1 Moore, Fraser
A1 Slee, Mark
A1 Saladino, Maria Laura
A1 Alroughani, Raed
A1 Shaw, Cameron
A1 Kasa, Krisztian
A1 Petkovska-Boskova, Tatjana
A1 den Braber-Moerland, Leontien
A1 Chapman, Joab
A1 Skromne, Eli
A1 Herbert, Joseph
A1 Poehlau, Dieter
A1 Needham, Merrilee
A1 Bacile Bacile, Elizabeth Alejandra
A1 Arruda, Walter Oleschko
A1 Paine, Mark
A1 Singhal, Bhim
A1 Vucic, Steve
A1 Cabrera-Gomez, Jose Antonio
A1 Butzkueven, Helmut
K1 Interferón beta
K1 Relación dosis-respuesta a droga
K1 Inyecciones subcutáneas
K1 Funciones de verosimilitud
K1 Esclerosis múltiple
K1 Espectroscopía de resonancia magnética
K1 Reproducibilidad de los resultados
K1 Resultado del tratamiento
K1 Privación del tratamiento
K1 Adulto
K1 Esclerosis múltiple
K1 Cumplimiento y adherencia al tratamiento
AB OBJECTIVESTo compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics.METHODSTreatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon β-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon β-1a in either dosage (22 µg or 44 µg) as their first disease modifying agent, matched on propensity score calculated from pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also had baseline MRI variables recorded.RESULTSOverall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as "lack of efficacy" (3.3% vs. 1.7%), "scheduled stop" (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation rate, 22 µg vs. 44 µg dosage, respectively). Propensity score was determined by treating centre and disability (score without MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched patients treated with either of the interferon dosages.CONCLUSIONSTreatment discontinuations were more common in interferon β-1a 22 µg SC thrice weekly. However, 2-year clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived from "real-world" database the results of the pivotal randomised trial. Propensity score matching effectively minimised baseline covariate imbalance between two directly compared sub-populations from a large observational registry.
PB Public Library of Science
YR 2013
FD 2013-05-21
LK http://hdl.handle.net/10668/2930
UL http://hdl.handle.net/10668/2930
LA en
NO Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G, Grammond P, et al. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS ONE. 2013; 8(5):e63480
NO Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't;
NO This study was funded by MSBase Foundation, a not-for-profit organisation. The MSBase Foundation receives financial support from Merck Serono, Biogen Idec, Novartis Pharma, Bayer Schering and Sanofi Aventis. The study was also funded by Multiple Sclerosis Research Australia and MSAngels. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
DS RISalud
RD Apr 7, 2025